Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aimmune Accelerates Commercial Planning For Peanut Allergy Drug

Executive Summary

Even better than expected efficacy and safety in the Phase III PALISADE trial puts Aimmune on track to file its BLA for peanut protein capsule AR101 by the end of 2018.


Related Content

Finance Watch: Recent Offerings Show Some Companies Were Ready For The Government Shutdown
Finance Watch: Not Everyone Can Go Public, But Biopharma IPOs Are Using Multiple Markets
Under The Radar: Potential Small Cap Takeover Targets
Keeping Track: A Long-Awaited Approval For Generic EpiPen, Cancer Product Labels Expand And Constrict
ICER’s 2019 Agenda Includes CAR-T Therapy, Drugs For Depression, Arthritis, AMD
Eight Pivotal Trial Read-Outs Expected In Q3
Finance Watch: The Curious Case Of Proteostasis' Short Attack
DBV Technologies Misses With Viaskin Peanut Allergy Patch
Aimmune Gets $145m From Nestlé To Advance Food Allergy Immunotherapies
'Breakthrough' status granted to Aimmune's peanut allergy drug


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts